Unverified85% confidenceDecision RuleTime unknown
新一代COX-2选择性抑制剂(罗贝考昔Onsior、非罗考昔Previcox、地拉考昔Deramaxx)比老一代(卡洛芬、美洛昔康)消化道刺激更小,适合需长期用药的关节炎老犬
1
Sources
85%
Confidence
Long-term
Relevance
-
First Seen
Sources
Related Entities
Related Claims
Unverified犬类骨关节炎慢性疼痛首选兽用COX-2选择性NSAIDs(如美洛昔康、卡洛芬、非罗考昔),相比非选择性药物胃肠道和肾脏副作用更低,适合长期用药78% similarUnverifiedCOX-2选择性越高消化道越安全,但选择性过高的产品对肾脏保护作用也减弱;对健康成年犬短期镇痛,卡洛芬等经典药物性价比与安全性平衡更好78% similarUnverified选择性COX-2抑制剂(卡洛芬、罗贝考昔、地拉考昔)比非选择性NSAID(阿司匹林、酮洛芬)胃肠道副作用更小,但价格更高;短期术后镇痛用非选择性够用,长期慢病管理选COX-2选择性77% similarUnverified犬骨关节炎慢性疼痛首选宠物专用NSAIDs(如卡洛芬、美洛昔康、非罗考昔),选择性COX-2抑制剂胃肠道副作用低于非选择性药物73% similarUnverified选择性COX-2抑制剂(如塞来昔布、依托考昔)胃肠道副作用显著低于传统NSAIDs,胃溃疡病史或60岁以上人群优先选择,但心血管高危患者慎用72% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/295807API
curl https://kongchang.com/api/v1/knowledge/claims/295807MCP
get_claim(id=295807)